Candel Therapeutics Is A Clinical Stage Biopharmaceutical Company Based In Needhammassachusettsit Focuses On Developing Viral Immunotherapies That Activate The Immune System Against Cancer Through An In Situ Vaccination Mechanismthe Company Is Publicly Traded On Nasdaq Under The Ticker Cadl And Specializes In Off The Shelf Multimodal Biological Immunotherapies That Induce Systemic Anti Tumor Immune Responses Candel Operates At The Intersection Of Oncolytic Virotherapy And Immunotherapyutilizing Genetically Modified Viruses To Promote Immunogenic Cell Death In Cancer Cellstheir Lead Candidatecan 2409Is In Phase 2 3 Trials For Non Small Cell Lung Cancerborderline Resectable Pancreatic Cancerand Localized Prostate Canceradditionallycan 3110 Is An Investigational Therapy In A Phase 1 Trial For Recurrent High Grade Gliomacandel S Approach Combines Direct Tumor Destruction With Immune Stimulationaiming To Create Personalized Anti Cancer Responses Without The Need For Patient Specific Customization
